Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Larotrectinib in pediatric patients with advanced solid or primary CNS tumors with NTRK fusion
2022-502668-20-00Phase 2Completed
- Sponsor
- Bayer
- Start
- Apr 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 21
01
Overview
Phase 2, open-label trial of larotrectinib in Nonhematologic neoplasms, Central nervous system tumor harboring NTRK gene fusion, congenital fibrosarcoma (CFS) and 3 more (2 arms), sponsored by Bayer. Primary endpoints: Dose-limiting toxicity, Treatment-emergent adverse events and 2 more. Started Apr 2017; status: completed.
02
Drugs
larotrectinib
03
Conditions
Nonhematologic neoplasmsCentral nervous system tumor harboring NTRK gene fusioncongenital fibrosarcoma (CFS)mesoblastic nephroma (CMN)secretory breast carcinoma (SBC)
Beyond the preview
Go deeper on 2022-502668-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502668-20-00.